SG11202006470RA - Use of 5-fluoro-4-(4-fluoro-2-methoxyphenyl)-n-{4-[(s-methylsulfonimidoyl)methyl]pyridin-2-yl}pyridin-2-amine for treating diffuse large b-cell lymphoma - Google Patents
Use of 5-fluoro-4-(4-fluoro-2-methoxyphenyl)-n-{4-[(s-methylsulfonimidoyl)methyl]pyridin-2-yl}pyridin-2-amine for treating diffuse large b-cell lymphomaInfo
- Publication number
- SG11202006470RA SG11202006470RA SG11202006470RA SG11202006470RA SG11202006470RA SG 11202006470R A SG11202006470R A SG 11202006470RA SG 11202006470R A SG11202006470R A SG 11202006470RA SG 11202006470R A SG11202006470R A SG 11202006470RA SG 11202006470R A SG11202006470R A SG 11202006470RA
- Authority
- SG
- Singapore
- Prior art keywords
- pyridin
- fluoro
- methylsulfonimidoyl
- methoxyphenyl
- amine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18156576 | 2018-02-13 | ||
| PCT/EP2019/053407 WO2019158517A1 (en) | 2018-02-13 | 2019-02-12 | Use of 5-fluoro-4-(4-fluoro-2-methoxyphenyl)-n-{4-[(s-methylsulfonimidoyl)methyl]pyridin-2-yl}pyridin-2-amine for treating diffuse large b-cell lymphoma |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202006470RA true SG11202006470RA (en) | 2020-08-28 |
Family
ID=61223765
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202006470RA SG11202006470RA (en) | 2018-02-13 | 2019-02-12 | Use of 5-fluoro-4-(4-fluoro-2-methoxyphenyl)-n-{4-[(s-methylsulfonimidoyl)methyl]pyridin-2-yl}pyridin-2-amine for treating diffuse large b-cell lymphoma |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US11701347B2 (en) |
| EP (1) | EP3752487A1 (en) |
| JP (1) | JP7280286B2 (en) |
| KR (1) | KR20200119800A (en) |
| CN (1) | CN111727183B (en) |
| AU (1) | AU2019221019B2 (en) |
| BR (1) | BR112020016389A2 (en) |
| CA (1) | CA3090843A1 (en) |
| CL (1) | CL2020002087A1 (en) |
| EA (1) | EA202091894A1 (en) |
| IL (1) | IL276437B2 (en) |
| JO (1) | JOP20200196A1 (en) |
| MA (1) | MA51820A (en) |
| MX (1) | MX2020008447A (en) |
| SG (1) | SG11202006470RA (en) |
| WO (1) | WO2019158517A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2020008447A (en) | 2018-02-13 | 2020-09-28 | Bayer Ag | Use of 5-fluoro-4-(4-fluoro-2-methoxyphenyl)-n-{4-[(s-methylsulfo nimidoyl)methyl]pyridin-2-yl}pyridin-2-amine for treating diffuse large b-cell lymphoma. |
Family Cites Families (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1307271A (en) | 1970-06-25 | 1973-02-14 | Shell Int Research | Sulphoximine derivatives and their use in herbicidal compositions |
| MXPA02003436A (en) | 1999-10-07 | 2002-08-20 | Amgen Inc | Triazine kinase inhibitors. |
| HU230574B1 (en) | 2000-12-21 | 2023-11-28 | Novartis Ag | Pyrimidineamines as angiogenesis modulators and pharmaceutical compositions containing them |
| GB0103926D0 (en) | 2001-02-17 | 2001-04-04 | Astrazeneca Ab | Chemical compounds |
| US7291616B2 (en) | 2001-10-31 | 2007-11-06 | Cell Therapeutics, Inc. | Aryl triazines as LPAAT-β inhibitors and uses thereof |
| DK2256108T3 (en) | 2002-07-18 | 2016-04-11 | Janssen Pharmaceutica Nv | Substituted triazinkinaseinhibitorer |
| DE10239042A1 (en) | 2002-08-21 | 2004-03-04 | Schering Ag | New fused macrocyclic pyrimidine derivatives, useful as e.g. cyclin-dependent kinase inhibitors for treating e.g. cancer, autoimmune, cardiovascular or neurodegenerative diseases or viral infections |
| JP2006518381A (en) | 2003-02-07 | 2006-08-10 | バーテックス ファーマシューティカルズ インコーポレイテッド | Heteroaryl-substituted pyrroles useful as inhibitors of protein kinases |
| WO2005026129A1 (en) | 2003-09-15 | 2005-03-24 | Gpc Biotech Ag | Pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases |
| DE10349423A1 (en) | 2003-10-16 | 2005-06-16 | Schering Ag | Sulfoximine-substituted parimidines as CDK and / or VEGF inhibitors, their preparation and use as medicaments |
| ES2333977T3 (en) | 2004-10-05 | 2010-03-03 | Syngenta Limited | ISOXAZOLINE DERIVATIVES AND ITS USE AS HERBICIDES. |
| US20090099160A1 (en) | 2004-12-17 | 2009-04-16 | David Andrews | 4-(4-(Imidazol-4-Yl) Pyrimidin-2-Ylamino) Benzamides as CDK Inhibitors |
| DE102005062742A1 (en) | 2005-12-22 | 2007-06-28 | Bayer Schering Pharma Ag | New sulfoximine-substituted pyrimidines useful for treating e.g. diseases caused by inflammatory, allergic or proliferative processes, oncological diseases, cancer, eye, autoimmune and neurodegerative diseases |
| EP1803723A1 (en) | 2006-01-03 | 2007-07-04 | Bayer Schering Pharma Aktiengesellschaft | (2,4,9-triaza-1(2,4)-pyrimidina-3(1,3)-benzenacyclononaphan-3^4-yl)-sulfoximide derivatives as selective inhibitors of the aurora kinase for the treatment of cancer |
| JP4305477B2 (en) | 2006-07-25 | 2009-07-29 | トヨタ自動車株式会社 | Spark ignition internal combustion engine |
| DE102006041382A1 (en) | 2006-08-29 | 2008-03-20 | Bayer Schering Pharma Ag | Carbamoyl sulfoximides as protein kinase inhibitors |
| DE102006042143A1 (en) | 2006-09-08 | 2008-03-27 | Bayer Healthcare Aktiengesellschaft | Novel substituted bipyridine derivatives and their use |
| WO2008060248A1 (en) | 2006-11-15 | 2008-05-22 | S*Bio Pte Ltd. | Indole sustituted pyrimidines and use thereof in the treatment of cancer |
| EP2094682A2 (en) | 2006-12-22 | 2009-09-02 | Novartis AG | Heteroaryl-heteroaryl compounds as cdk inhibitors for the treatment of cancer, inflammation and viral infections |
| AU2007336918A1 (en) | 2006-12-22 | 2008-07-03 | Novartis Ag | Indol-4-yl-pyrimidinyl-2-yl-amine derivatives and use thereof as cyclin dependant kinase inhibitors |
| MX2009009792A (en) | 2007-03-12 | 2009-09-23 | Cytopia Res Pty Ltd | Phenyl amino pyrimidine compounds and uses thereof. |
| US8507498B2 (en) | 2007-04-24 | 2013-08-13 | Ingenium Pharmaceuticals Gmbh | 4, 6-disubstituted aminopyrimidine derivatives as inhibitors of protein kinases |
| JP5693951B2 (en) | 2007-04-24 | 2015-04-01 | アストラゼネカ エービー | Protein kinase inhibitors |
| JP5379787B2 (en) | 2007-04-24 | 2013-12-25 | インゲニウム ファーマシューティカルズ ジーエムビーエイチ | Protein kinase inhibitors |
| WO2008132138A1 (en) | 2007-04-25 | 2008-11-06 | Ingenium Pharmaceuticals Gmbh | Derivatives of 4,6-disubstituted aminopyrimidines |
| CA2698511C (en) | 2007-09-04 | 2016-10-11 | The Scripps Research Institute | Substituted pyrimidinyl-amines as protein kinase inhibitors |
| WO2009029998A1 (en) | 2007-09-06 | 2009-03-12 | Cytopia Research Pty Ltd | Retrometabolic compounds |
| GB0805477D0 (en) | 2008-03-26 | 2008-04-30 | Univ Nottingham | Pyrimidines triazines and their use as pharmaceutical agents |
| AU2009271019A1 (en) | 2008-07-14 | 2010-01-21 | Gilead Sciences, Inc. | Fused heterocyclyc inhibitors of histone deacetylase and/or cyclin-dependent kinases |
| US8415381B2 (en) | 2009-07-30 | 2013-04-09 | Novartis Ag | Heteroaryl compounds and their uses |
| WO2011026917A1 (en) | 2009-09-04 | 2011-03-10 | Novartis Ag | Heteroaryl compounds as kinase inhibitors |
| TW201111378A (en) | 2009-09-11 | 2011-04-01 | Bayer Schering Pharma Ag | Substituted (heteroarylmethyl) thiohydantoins |
| AU2010306927A1 (en) | 2009-10-12 | 2012-05-31 | Myrexis, Inc. | Amino - pyrimidine compounds as inhibitors of TBKL and/or IKK epsilon |
| ES2619585T3 (en) | 2010-03-22 | 2017-06-26 | Lead Discovery Center Gmbh | Pharmaceutically active disubstituted triazine derivatives |
| DE102010046720A1 (en) | 2010-09-23 | 2012-03-29 | Bayer Schering Pharma Aktiengesellschaft | Process for the preparation of pan-CDK inhibitors of the formula (I), as well as intermediates of the preparation |
| WO2012066065A1 (en) | 2010-11-17 | 2012-05-24 | Novartis Ag | Phenyl-heteroaryl amine compounds and their uses |
| JP2013542967A (en) | 2010-11-17 | 2013-11-28 | ノバルティス アーゲー | 3- (Aminoaryl) -pyridine compound |
| WO2012101064A1 (en) | 2011-01-28 | 2012-08-02 | Novartis Ag | N-acyl pyrimidine biaryl compounds as protein kinase inhibitors |
| CN103339110A (en) | 2011-01-28 | 2013-10-02 | 诺瓦提斯公司 | Substituted bi-heteroaryl compounds as cdk9 inhibitors and their uses |
| WO2012101066A1 (en) | 2011-01-28 | 2012-08-02 | Novartis Ag | Pyridine biaryl amine compounds and their uses |
| WO2012101063A1 (en) | 2011-01-28 | 2012-08-02 | Novartis Ag | N-acyl pyridine biaryl compounds and their uses |
| WO2012101065A2 (en) | 2011-01-28 | 2012-08-02 | Novartis Ag | Pyrimidine biaryl amine compounds and their uses |
| US9242937B2 (en) | 2011-03-02 | 2016-01-26 | Bayer Intellectual Property Gmbh | Pharmaceutically active disubstituted pyridine derivatives |
| US9226929B2 (en) | 2011-03-02 | 2016-01-05 | Bayer Intellectual Property Gmbh | Pharmaceutically active disubstituted triazine derivatives |
| US20140288044A1 (en) | 2011-04-12 | 2014-09-25 | Alzheimer's Institute Of America, Inc. | Compositions and therapeutic uses of ikk-related kinase epsilon and tankbinding kinase 1 inhibitors |
| CN102731413A (en) | 2011-04-15 | 2012-10-17 | 上海医药工业研究院 | Urea compound and its preparation method, intermediate and use |
| US8916557B2 (en) | 2011-04-19 | 2014-12-23 | Bayer Intellectual Property Gmbh | Substituted 4-Aryl-N-phenyl-1,3,5-triazin-2-amines |
| EP2527332A1 (en) | 2011-05-24 | 2012-11-28 | Bayer Intellectual Property GmbH | 4-Aryl-N-phenyl-1,3,5-triazin-2-amines containing a sulfoximine group as CDK9 inhibitors |
| TWI555737B (en) | 2011-05-24 | 2016-11-01 | 拜耳知識產權公司 | 4-aryl-n-phenyl-1,3,5-triazin-2-amines containing a sulfoximine group |
| JP5982490B2 (en) | 2011-09-16 | 2016-08-31 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ | Disubstituted 5-fluoro-pyrimidine |
| WO2013037894A1 (en) | 2011-09-16 | 2013-03-21 | Bayer Intellectual Property Gmbh | Disubstituted 5-fluoro pyrimidine derivatives containing a sulfoximine group |
| EP2909183B1 (en) | 2012-10-18 | 2016-08-24 | Bayer Pharma Aktiengesellschaft | 4-(ortho)-fluorophenyl-5-fluoropyrimidin-2-yl amines containing a sulfone group |
| NZ707084A (en) | 2012-11-15 | 2019-09-27 | Bayer Pharma AG | 5-fluoro-n-(pyridin-2-yl)pyridin-2-amine derivatives containing a sulfoximine group |
| WO2014076028A1 (en) | 2012-11-15 | 2014-05-22 | Bayer Pharma Aktiengesellschaft | 4-(ortho)-fluorophenyl-5-fluoropyrimidin-2-yl amines containing a sulfoximine group |
| ES2630115T3 (en) | 2013-07-04 | 2017-08-18 | Bayer Pharma Aktiengesellschaft | 5-Fluoro-n- (pyridin-2-yl) pyridin-2-amine derivatives with substituted sulfoximin and its use as cdk9 kinase inhibitors |
| CA2942119A1 (en) | 2014-03-13 | 2015-09-17 | Bayer Pharma Aktiengesellschaft | 5-fluoro-n-(pyridin-2-yl)pyridin-2-amine derivatives containing a sulfone group |
| EP3273963A1 (en) * | 2015-03-24 | 2018-01-31 | Bayer Pharma Aktiengesellschaft | Use of 4-(4-fluoro-2-methoxyphenyl)-n-{3-[(s-methylsulfonimidoyl)methyl]phenyl}-1,3,5-triazin-2-amine for treating lymphomas |
| MX2020008447A (en) | 2018-02-13 | 2020-09-28 | Bayer Ag | Use of 5-fluoro-4-(4-fluoro-2-methoxyphenyl)-n-{4-[(s-methylsulfo nimidoyl)methyl]pyridin-2-yl}pyridin-2-amine for treating diffuse large b-cell lymphoma. |
-
2019
- 2019-02-12 MX MX2020008447A patent/MX2020008447A/en unknown
- 2019-02-12 CN CN201980013294.2A patent/CN111727183B/en active Active
- 2019-02-12 IL IL276437A patent/IL276437B2/en unknown
- 2019-02-12 JP JP2020565543A patent/JP7280286B2/en active Active
- 2019-02-12 EP EP19704618.8A patent/EP3752487A1/en active Pending
- 2019-02-12 AU AU2019221019A patent/AU2019221019B2/en active Active
- 2019-02-12 SG SG11202006470RA patent/SG11202006470RA/en unknown
- 2019-02-12 US US16/969,460 patent/US11701347B2/en active Active
- 2019-02-12 CA CA3090843A patent/CA3090843A1/en active Pending
- 2019-02-12 WO PCT/EP2019/053407 patent/WO2019158517A1/en unknown
- 2019-02-12 JO JOP/2020/0196A patent/JOP20200196A1/en unknown
- 2019-02-12 BR BR112020016389-9A patent/BR112020016389A2/en unknown
- 2019-02-12 EA EA202091894A patent/EA202091894A1/en unknown
- 2019-02-12 KR KR1020207022928A patent/KR20200119800A/en not_active Application Discontinuation
- 2019-02-12 MA MA051820A patent/MA51820A/en unknown
-
2020
- 2020-08-12 CL CL2020002087A patent/CL2020002087A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2019158517A1 (en) | 2019-08-22 |
| KR20200119800A (en) | 2020-10-20 |
| IL276437A (en) | 2020-09-30 |
| MX2020008447A (en) | 2020-09-28 |
| IL276437B2 (en) | 2024-03-01 |
| IL276437B1 (en) | 2023-11-01 |
| BR112020016389A2 (en) | 2020-12-15 |
| JP2021514386A (en) | 2021-06-10 |
| JOP20200196A1 (en) | 2020-08-13 |
| CA3090843A1 (en) | 2019-08-22 |
| US20210015806A1 (en) | 2021-01-21 |
| CL2020002087A1 (en) | 2020-12-11 |
| CN111727183B (en) | 2023-12-29 |
| AU2019221019B2 (en) | 2024-05-02 |
| AU2019221019A1 (en) | 2020-07-23 |
| CN111727183A (en) | 2020-09-29 |
| US11701347B2 (en) | 2023-07-18 |
| EA202091894A1 (en) | 2020-12-28 |
| EP3752487A1 (en) | 2020-12-23 |
| JP7280286B2 (en) | 2023-05-23 |
| MA51820A (en) | 2021-05-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL281597A (en) | Rnai agents for inhibiting expression of 17beta-hsd type 13- (hsd17b13), compositions thereof, and methods of use | |
| EP3678597A4 (en) | Axisymmetric adjustable device for treating mitral regurgitation | |
| IL287145A (en) | Methods of treating non-hodgkin lymphoma using 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione | |
| PT3805233T (en) | (r) and (s) enantiomer of n-(5-(3-hydroxypyrrolidin-1-yl)-2-morpholinooxazolo[4,5-b]pyridin-6-yl)-2-(2-methylpyridin-4-yl)oxazole-carboxamide as irak4 inhibitors for treating cancer and inflammatory diseases | |
| KR102116867B9 (en) | Surface treatment device for implant | |
| IL274394A (en) | Compounds and methods for reducing snca expression | |
| IL282006A (en) | Treating essential tremor using (r)-2-(4-isopropylphenyl)-n-(1-(5-(2,2,2-trifluoroethoxy)pyridin-2-yl)ethyl)acetamide | |
| DK3490625T3 (en) | Device with structured coating for use as an implant for the treatment of perforations in the eardrum | |
| PL3797107T3 (en) | Heterocondensed pyridone compounds and their use as idh inhibitors | |
| ZA202204809B (en) | 5-ht2a agonists for use in treatment of depression | |
| IL280721A (en) | Treatment of relapsed follicular lymphoma | |
| IL285546A (en) | Compounds and methods for reducing kcnt1 expression | |
| SG11202009171XA (en) | Surface treatment method of wafer and composition used for said method | |
| IL276437A (en) | Use of 5-fluoro-4-(4-fluoro-2-methoxyphenyl)-n-{4-[(s-methylsulfonimidoyl)methyl]pyridin-2-yl}pyridin-2-amine for treating diffuse large b-cell lymphoma | |
| IL273909A (en) | Treatment of cd20-positive b-cell lymphoma with obituzumab | |
| IL292235A (en) | Methods of using anti-cd79b immunoconjugates to treat diffuse large b-cell lymphoma | |
| EP3442015A4 (en) | Wafer holding mechanism and method for rotary table and rotary wafer holding device | |
| IL288900A (en) | Treatment comprising fxr agonists | |
| IL288440A (en) | Compositions and methods for treating retinopathy | |
| DK4036095T3 (en) | 4-FLUORO-1H-PYRAZOLO[3,4-C]PYRIDINE DERIVATIVES AS SELECTIVE BRUTON TYROSINE KINASE (BTK) INHIBITORS FOR THE TREATMENT OF B-CELL LYMPHOMA AND AUTOIMMUNE DISEASES | |
| IL275384A (en) | Methods and compositions for pre-emptive treatment of graft versus host disease | |
| ZA202007320B (en) | Compounds for pain treatment, compositions comprising same, and methods of using same | |
| EP3873498A4 (en) | Methods and compositions for treating hepatocellular carcinoma using antisense | |
| MX2020005557A (en) | Fxr agonists for the treatment of liver diseases. | |
| IL283054A (en) | Methods of treating myelodysplastic syndrome |